Debevoise Advises J.P. Morgan Securities as Financial Advisor to Allergan in Its Sale to AbbVie for $63 Billion in Cash, Stock

25 June 2019

Debevoise & Plimpton LLP is advising J.P. Morgan Securities LLC (NYSE: JPM) as financial advisor to Allergan plc (NYSE: AGN), a pharmaceutical company, in connection with its sale to AbbVie Inc. (NYSE: ABBV). The sale consists of a cash and stock transaction for a transaction equity value of approximately $63 billion. The transaction represents a 45% premium to the closing price of Allergan's shares on June 24, 2019.

J.P. Morgan Securities offers a broad array of investment products and investment management services. Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products. AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions.

The Debevoise team is led by partner Andrew Bab and includes associates Thomas V. Lopez and Rafael Thor.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.